Experimental human influenza: Observations from studies of influenza antivirals

Antiviral Therapy

Volumn 17, Issue 1 PART B, 2012, Pages 133-141

  Hayden, Frederick G ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; AMITIVIR; ANTIVIRUS AGENT; IMMUNOGLOBULIN M; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; OSELTAMIVIR; PARACETAMOL; PERAMIVIR; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIMANTADINE; TUMOR NECROSIS FACTOR ALPHA; ZANAMIVIR;

ANTIBODY TITER; ANTIVIRAL SUSCEPTIBILITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESEARCH; DRUG TOLERABILITY; ECG ABNORMALITY; EXPERIMENTAL INFECTION; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H2N2); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VIRUS A; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS B; INOCULATION; LOADING DRUG DOSE; LOW DRUG DOSE; MEDICAL RESEARCH; MYOCARDIAL DISEASE; NONHUMAN; OTALGIA; OTITIS MEDIA; OUTCOME ASSESSMENT; PATHOGENESIS; POST EXPOSURE PROPHYLAXIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS; REVIEW; RISK ASSESSMENT; SAFETY; SEROCONVERSION; SINGLE DRUG DOSE; SINUSITIS; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860323111     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2062     Document Type: Review

References (70)

1. Smorodintseff AA, Tushinsky MD, Drobyshevskaya AI, Korovin AA, Osetroff AI. Investigation of volunteers infected with the influenza virus. Am J Med Sci 1937; 194:159-170.
2. Henle W, Henle G, Stokes J, Jr., Morris E P. Experimental exposure of human subjects to viruses of influenza. J Immunol 1946; 52:145-165.
3. Knight V, Kasel JA, Alford RH, et al. New research on influenza: studies with normal volunteers. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med 1965; 62:1307-1325.
4. Jao RL, Wheelock E F, Jackson GG. Production of interferon in volunteers infected with Asian influenza. J Infect Dis 1970; 121:419-426.
5. Alford RH, Kasel JA, Gerone PJ, Knight V. Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med 1966; 122:800-804.
6. Keitel WA, Couch RB, Cate TR, Six HR, Baxter BD. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis 1990; 161:22-26. (Pubitemid 20021851)
7. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275:295-299. (Pubitemid 26028588)
8. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167:775-785. (Pubitemid 351451744)
9. Little J W, Douglas RG, Jr., Hall WJ, Roth FK. Attenuated influenza produced by experimental intranasal inoculation. J Med Virol 1979; 3:177-188. (Pubitemid 9155020)
10. Dawkins AT, Jr., Gallager LR, Togo Y, Hornick RB, Harris BA. Studies on induced influenza in man. II. Double-blind study designed to assess the prophylactic efficacy of an analogue of amantadine hydrochloride. JAMA 1968; 203:1095-1099.
11. Skoner DP, Doyle WJ, Seroky J, Fireman P. Lower airway responses to influenza A virus in healthy allergic and nonallergic subjects. Am J Respir Crit Care Med 1996; 154:661-664. (Pubitemid 26327288)
12. Bischoff WE, Reid T, Russell GB, Peters TR. Transocular entry of seasonal influenza-attenuated virus aerosols and the efficacy of N95 respirators, surgical masks, and eye protection in humans. J Infect Dis 2011; 204:193-199.
13. Ison MG, Campbell V, Rembold C, Dent J, Hayden FG. Cardiac findings during uncomplicated influenza in ambulatory adults. Clin Infect Dis 2005; 40:415-422. (Pubitemid 40216510)
14. Treanor J, Hayden FG. Volunteer challenge studies. In Nicolson KG, Webster RG, Hay AJ (Editors). Textbook of Influenza. Oxford: Blackwell Science Ltd, 1998; pp. 517-537.
15. Killingley B, Enstone J, Booy R, et al. Potential role of human challenge studies for investigation of influenza transmission. Lancet Infect Dis 2011; 11:879-886.
16. Jackson GG, Muldoon RL, Akers LW. Serological evidence for prevention of influenzal infection in volunteers by an anti-influenzal drug adamantanamine hydrochloride. Antimicrob Agents Chemother (Bethesda) 1963; 161:703-707.
17. Tyrrell DA, Bynoe ML, Hoorn B. Studies on the antiviral activity of 1-adamantanamine. Br J Exp Pathol 1965; 46:370-375.
18. Smorodintsev AA, Zlydnikov DM, Kiseleva AM, Romanov JA, Kazantsev AP, Rumovsky VI. Evaluation of amantadine in artificially induced A2 and B influenza. JAMA 1970; 213:1448-1454.
19. Zlydnikov DM, Kubar OI, Kovaleva TP, Kamforin LE. Study of rimantadine in the USSR: a review of the literature. Rev Infect Dis 1981; 3:408-421.
20. Beare AS, Hall TS, Tyrrell DA. Protection of volunteers against challenge with A-Hong Kong-68 influenza virus by a new adamantane compound. Lancet 1972; 1:1039-1040.
21. Al-Nakib W, Higgins PG, Willman J, et al. Prevention and treatment of experimental influenza A virus infection in volunteers with a new antiviral ICI 130,685. J Antimicrob Chemother 1986; 18:119-129. (Pubitemid 16070377)
22. Hayden FG, Zylidnikov DM, Iljenko VI, Padolka YV. Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection. Antiviral Res 1982; 2:147-153. (Pubitemid 12026890)
23. Merigan TC, Reed SE, Hall TS, Tyrrell DA. Inhibition of respiratory virus infection by locally applied interferon. Lancet 1973; 1:563-567.
24. Phillpotts RJ, Higgins PG, Willman JS, Tyrrell DA, Freestone DS, Shepherd WM. Intranasal lymphoblastoid interferon ('Wellferon') prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res 1984; 4:535-541. (Pubitemid 14023309)
25. Treanor JJ, Betts RF, Erb SM, Roth FK, Dolin R. Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. J Infect Dis 1987; 156:379-383. (Pubitemid 17098206)
26. Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM, Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med 1986; 314:71-75. (Pubitemid 16183081)
27. Douglas RM, Moore BW, Miles HB, et al. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med 1986; 314:65-70. (Pubitemid 16183080)
28. Tannock GA, Gillett SM, Gillett RS, et al. A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers. Epidemiol Infect 1988; 101:611-621. (Pubitemid 19035420)
29. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240-1246. (Pubitemid 29468495)
30. Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005; 10:901-910. (Pubitemid 43076341)
31. Calfee DP, Peng AW, Hussey EK, Lobo M, Hayden FG. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antivir Ther 1999; 4:143-149. (Pubitemid 29467114)
32. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186:1582-1588. (Pubitemid 35379634)
33. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000; 343:1282-1289.
34. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336-1343. (Pubitemid 29503572)
35. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43:1616-1620. (Pubitemid 29331237)
36. Hayden FG, Tunkel AR, Treanor JJ, Betts RF, Allerheiligen S, Harris J. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob Agents Chemother 1994; 38:1178-1181. (Pubitemid 24150862)
37. Hayden FG, Hall WJ, Douglas RG, Jr. Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. J Infect Dis 1980; 141:535-542. (Pubitemid 10109821)
38. Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000; 5:205-213.
39. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44:197-202. (Pubitemid 46079980)
40. Sato M, Saito R, Sato I, et al. Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan. Tohoku J Exp Med 2008; 214:113-120. (Pubitemid 351513543)
41. Togo Y, McCracken EA. Double-blind clinical assessment of ribavirin (virazole) in the prevention of induced infection with type B influenza virus. J Infect Dis 1976; 133 Suppl 2:A109-A113.
42. Cohen A, Togo Y, Khakoo R, Waldman R, Sigel M. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J Infect Dis 1976; 133 Suppl 2:A114-A120.
43. Magnussen CR, Douglas RG, Jr., Betts RF, Roth FK, Meagher M P. Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother 1977; 12:498-502. (Pubitemid 8192221)
44. Smith CB, Charette RP, Fox JP, Cooney MK, Hall CE. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J Infect Dis 1980; 141:548-554. (Pubitemid 10109823)
45. Stein DS, Creticos CM, Jackson GG, et al. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother 1987; 31:1285-1287. (Pubitemid 17157618)
46. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183:523-531. (Pubitemid 32147507)
47. Murphy BR, Baron S, Chalhub EG, Uhlendorf CP, Chanock RM. Temperature-sensitive mutants of influenza virus. IV. Induction of interferon in the nasopharynx by wild-type and a temperature-sensitive recombinant virus. J Infect Dis 1973; 128:488-493.
48. Ennis FA, Meager A, Beare AS, et al. Interferon induction and increased natural killer-cell activity in influenza infections in man. Lancet 1981; 2:891-893. (Pubitemid 11008427)
49. Fritz RS, Hayden FG, Calfee D P, et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999; 180:586-593. (Pubitemid 29411341)
50. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 1998; 101:643-649. (Pubitemid 28084248)
51. Skoner DP, Gentile DA, Patel A, Doyle WJ. Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. J Infect Dis 1999; 180:10-14. (Pubitemid 29293911)
52. Zaas AK, Chen M, Varkey J, et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 2009; 6:207-217.
53. Huang Y, Zaas AK, Rao A, et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLoS Genet 2011; 7:e1002234.
54. Buchman CA, Doyle WJ, Skoner DP, et al. Influenza A virus - induced acute otitis media. J Infect Dis 1995; 172:1348-1351.
55. Doyle WJ, Skoner D P, Alper CM, et al. Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis 1998; 177:1260-1265. (Pubitemid 28194264)
56. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80:275-282. (Pubitemid 17126807)
57. Walker JB, Hussey EK, Treanor JJ, Montalvo A, Jr., Hayden FG. Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. J Infect Dis 1997; 176:1417-1422. (Pubitemid 27518138)
58. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomised controlled trial. Clin Infect Dis 2010; 51:887-894.
59. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-133. (Pubitemid 32151932)
60. Kimberlin DW, Shalabi M, Abzug MJ, et al. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J 2010; 29:195-198
61. Monto AS, Shope TC, Schwartz SA, Albrecht JK. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection. J Infect Dis 1986; 154:128-133. (Pubitemid 16088311)
62. Gao L, Yu S, Chen Q, et al. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine 2010; 28:4445-4451.
63. Kaiser L, Henry D, Flack NP, Keene O, Hayden FG. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis 2000; 30:587-589. (Pubitemid 30205311)
64. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Jr., Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282:31-35. (Pubitemid 29318929)
65. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337:874-880. (Pubitemid 27408569)
66. Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:3234-3240.
67. Boivin G, Goyette N, Hardy I, Aoki F, Wagner A, Trottier S. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J Infect Dis 2000; 181:1471-1474. (Pubitemid 30252558)
68. Puhakka T, Lehti H, Vainionpaa R, et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis 2003; 35:52-58. (Pubitemid 36336368)
69. Halloran ME, Hayden FG, Yang Y, Longini MR, Jr., Monto AS. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 2006; 165:212-221. (Pubitemid 46096383)
70. Nishiura H, Oshitani H. Household transmission of influenza (H1N1-2009) in Japan: age-specificity and reduction of household transmission risk by zanamivir treatment. J Int Med Res 2011; 39:619-628.